
Nanobiotix SA (NBTX) Stock Forecast & Price Target
Nanobiotix SA (NBTX) Analyst Ratings
Bulls say
Nanobiotix is a promising biotechnology company with a unique and innovative approach to treating cancer through nanotechnology. The company's partnership with JNJ and recent positive data updates from their nanoenhancer NBTXR3 demonstrate potential for success in large commercial markets. However, there are risks such as execution, financial, and regulatory setbacks that could negatively impact the company's growth. Considering potential milestone payments and discounted cash flow analysis, we have set a price target of $46/share for the company.
Bears say
Nanobiotix is a clinical-stage biotechnology company that faces various risks in its development and commercialization of novel nanoparticle-based therapies for cancer treatment, including clinical trial failures, safety concerns, and regulatory setbacks. The company also has a significant amount of debt and may need additional financing before becoming cash flow positive. While it has potential for royalties and milestone payments through its collaboration with JNJ, the success of its lead program NBTXR3 in head and neck and lung cancers may not be fully realized. Additionally, the recent $71M royalty monetization agreement with HCRx should provide some short-term funding, but the company may still face execution and financial risks in the future. Overall, there are significant concerns about the company's ability to successfully navigate these challenges and achieve commercial success, leading to a negative outlook for its stock.
This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.
Nanobiotix SA (NBTX) Analyst Forecast & Price Prediction
Start investing in Nanobiotix SA (NBTX)
Order type
Buy in
Order amount
Est. shares
0 shares